|By PR Newswire||
|April 2, 2014 05:59 PM EDT||
LAMBERTVILLE, N.J., April 2, 2014 /PRNewswire/ -- CROnos Clinical Consulting, a global neuroscience focused clinical data quality control organization (QCO) with proven processes for delivering results, announced today that Dr. Nina Engelhardt has joined the Company as Vice President, Scientific Innovation. Dr. Engelhardt has been actively involved in innovations in trial methodology and clinical assessment to increase the success rate of placebo-controlled CNS trials for over 20 years.
"Nina is an exciting addition to our clinical team. We look forward to tapping into her expertise to deliver an improved product to our customers," said Guillermo Di Clemente, President and Founder, CROnos. "Her diverse experience provides an outstanding view of our market and its current and future innovations."
Dr. Engelhardt has over 20 years combined experience as a practicing clinician, research associate, and project manager. She has applied her skills both in and for the pharmaceutical industry since 1998 and has conducted research in the areas of psychological assessment in CNS trials, rater training and trial methodology. She has developed scale-specific training programs for staff at research sites worldwide.
Prior to joining CROnos, Dr. Engelhardt was Senior Clinical Trainer and Research Scientist for MedAvante and Senior Therapeutic Area Associate, New Antidepressants, Eli Lilly. She was a Clinical Research Associate in the Division of Clinical Psychopharmacology, Tufts-New England Medical Center. She received her doctorate in clinical psychology at Case Western Reserve University, after which she joined the faculty at Vanderbilt University.
In related activities, CROnos further strengthened its clinical expertise by establishing a consulting relationship with Dr. Mark W Jacobson. Dr. Jacobson adds his expertise in cognitive assessment to the company's expanding role in data monitoring and rater training for preclinical/dementia studies. Dr. Jacobson is a staff psychologist with Veterans Affairs Healthcare and an Assistant Adjunct Professor at UCSD School of Medicine. He has been a recipient of VA, NIH and Alzheimer's Association funded grants. Dr. Jacobson notes, "I have seen a growing emphasis on the detection of subtle prodromal markers during healthy aging. The innovative approaches applied to clinical assessment will demand a corresponding re-evaluation of traditional data monitoring methods and rater training. I believe CROnos is at the forefront of these innovations."
About CROnos Clinical Consulting Services
CROnos Clinical Consulting Services is a global provider of centralized risk-based data monitoring and data visualization solutions for neuroscience clinical trials. Our clients achieve high impact results from our proprietary technology, proven processes and scientific expertise to assess and confirm the credibility as well as accuracy of data necessary for approval and labeling of pharmaceutical products. For more information, please visit www.cronosccs.com.
SOURCE CROnos Clinical Consulting Services
We're entering the post-smartphone era, where wearable gadgets from watches and fitness bands to glasses and health aids will power the next technological revolution. With mass adoption of wearable devices comes a new data ecosystem that must be protected. Wearables open new pathways that facilitate the tracking, sharing and storing of consumers’ personal health, location and daily activity data. Consumers have some idea of the data these devices capture, but most don’t realize how revealing and...
May. 3, 2016 04:33 PM EDT
May. 3, 2016 04:15 PM EDT Reads: 1,238
May. 3, 2016 04:15 PM EDT Reads: 801
May. 3, 2016 04:15 PM EDT Reads: 134
May. 3, 2016 04:00 PM EDT Reads: 1,264
May. 3, 2016 04:00 PM EDT Reads: 971
May. 3, 2016 03:58 PM EDT Reads: 107
May. 3, 2016 03:45 PM EDT Reads: 1,053
May. 3, 2016 03:30 PM EDT Reads: 1,159
May. 3, 2016 03:15 PM EDT Reads: 1,043
May. 3, 2016 03:15 PM EDT Reads: 644
May. 3, 2016 03:15 PM EDT Reads: 1,137
May. 3, 2016 03:15 PM EDT Reads: 1,142
May. 3, 2016 02:30 PM EDT Reads: 933
May. 3, 2016 02:30 PM EDT Reads: 914